Physician profile
Alberto A Borges
NPI 1962531418
$2,916.42
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $143 · 2020: $813 · 2021: $1,216 · 2022: $593 · 2023: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $151.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $442.68 | 2019-2023 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $418.80 | 2019-2022 | |
| Abbvie INC. | $356.69 | 2021-2023 | Vraylar |
| Lilly USA, LLC | $239.65 | 2020-2022 | |
| Esperion Therapeutics, INC. | $204.61 | 2020-2023 | Nexletol |
| Janssen Pharmaceuticals, INC | $191.01 | 2020-2023 | Xarelto |
| Horizon Therapeutics Plc | $176.41 | 2020-2022 | |
| Glaxosmithkline, LLC. | $161.47 | 2020-2023 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.11 | 2019-2022 | |
| Pfizer INC. | $120.95 | 2020-2021 | |
| Redhill Biopharma INC. | $108.28 | 2020-2022 | |
| Amarin Pharma, INC. | $85.68 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $78.46 | 2020-2021 | |
| Allergan, INC. | $70.95 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $39.66 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $32.45 | 2022-2023 | Seglentis |
| Supernus Pharmaceuticals, INC. | $30.78 | 2019 | |
| Hologic Sales and Service, LLC | $19.66 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alberto Borges listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.